Drugs / NYMO32
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06827080 | Feb 2025 → Dec 2026 expected | prostate carcinoma | Zhengguo Chen | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYMO32 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06827080 ↗ |
| Modality | Other / unclassified | “radiopharmaceutical labeled with a PSMA ligand” NCT06827080 ↗ |